416 related articles for article (PubMed ID: 12188412)
41. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
[TBL] [Abstract][Full Text] [Related]
42. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
Bird PA; Hill AG; Houssami N
Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976
[TBL] [Abstract][Full Text] [Related]
43. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
[TBL] [Abstract][Full Text] [Related]
44. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
45. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
46. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.
Radhika K; Prayaga AK
Indian J Cancer; 2010; 47(2):148-50. PubMed ID: 20448377
[TBL] [Abstract][Full Text] [Related]
47. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
48. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
Tewari M; Pradhan S; Singh U; Shukla HS
Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
50. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
51. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy.
Cahill RA; Walsh D; Landers RJ; Watson RG
Ann Surg Oncol; 2006 Jan; 13(1):45-51. PubMed ID: 16378157
[TBL] [Abstract][Full Text] [Related]
52. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors].
Ellinidi VN; Anikseeva NV; Goncharova OA; Krasnozhon DA; Fedorov KA
Vopr Onkol; 2004; 50(2):234-6. PubMed ID: 15176229
[TBL] [Abstract][Full Text] [Related]
53. Ratio of concentrations of estrogen receptors to progesterone receptors (ER/PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR).
Hochmann J
Neoplasma; 2007; 54(4):290-6. PubMed ID: 17822318
[TBL] [Abstract][Full Text] [Related]
54. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
56. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
58. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
[TBL] [Abstract][Full Text] [Related]
59. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
[TBL] [Abstract][Full Text] [Related]
60. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]